none
Conditions
Interventions
Healthy volunteers will receive intravenous administration of the novel PET tracer [11C]OCS5, followed by whole-body and brain dynamic imaging using a PET scanner.
Sponsors
Yamasue Hidenori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Males and females aged 18 years or older but under 55 years at the time of consent acquisition (2) Healthy individuals with no past medical history (excluding infectious diseases that do not leave sequelae) or current medical conditions (3) Individuals for whom written consent to participate in this study has been obtained from the subject themselves
Exclusion criteria
Exclusion criteria: (1)Individuals diagnosed with a mental disorder or intellectual disability (2) Use of psychotropic medications within the past 6 months (3) Pregnant individuals, breastfeeding individuals, or individuals who may be pregnant (4) History of hypersensitivity to oxytocin (5) History of epileptic seizures or head trauma with loss of consciousness lasting 5 minutes or longer (6) History of alcohol-related disorders or other substance-related disorders (7)Individuals with serious concomitant medical conditions (8) Individuals with severe allergies or idiosyncrasies, such as anaphylaxis (9) Individuals unable to agree to use contraception during the study period (10) Individuals who participated in another PET study (involving radiation exposure) within one year prior to obtaining consent (11) Other individuals deemed ineligible for this study by the principal investigator (or co-investigator)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Whole-Body Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and Exposure Levels of the OXTR-PET Tracer [11C]OCS5 | — |
Contacts
Public ContactMasamichi Yokokura
Hamamatsu University School of Medicine
Outcome results
None listed